Ph.D. Kiernan Seth - 28 Feb 2023 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Role
VP, Chief Commercial Officer
Signature
/s/ Kiernan Seth, Ph.D.
Issuer symbol
LXRX
Transactions as of
28 Feb 2023
Net transactions value
-$25,634
Form type
4
Filing time
01 Mar 2023, 15:55:29 UTC
Previous filing
13 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXRX Common Stock Options Exercise +14,833 +68% 36,700 28 Feb 2023 Direct F1
transaction LXRX Common Stock Options Exercise +5,286 +14% 41,986 28 Feb 2023 Direct F1
transaction LXRX Common Stock Options Exercise +22,963 +55% 64,949 28 Feb 2023 Direct F1
transaction LXRX Common Stock Tax liability $25,634 -11,813 -18% $2.17 53,136 28 Feb 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LXRX Restricted Stock Units Options Exercise -14,833 -100% 0 28 Feb 2023 Common Stock 14,833 Direct F1, F3
transaction LXRX Restricted Stock Units Options Exercise -5,286 -50% 5,287 28 Feb 2023 Common Stock 5,286 Direct F1, F3
transaction LXRX Restricted Stock Units Options Exercise -22,963 -33% 45,927 28 Feb 2023 Common Stock 22,963 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock.
F2 Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
F3 Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.